About Ramanath Bhandari
Form D filings for RevOpsis Therapeutics from 2022 to 2024 list Ramanath Bhandari as chief executive officer.
Ramanath Bhandari first appears on SEC filings in 2022.
Experience
This experience comes from SEC filings. The years are when the filings name Ramanath Bhandari in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Ramanath Bhandari works with at each company, as listed on that company's latest Form D.
RevOpsis Therapeutics, Inc. · Form D, Nov 7, 2024
RP
Ram Palanki
Director